Acuta Capital Partners LLC Cuts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Acuta Capital Partners LLC cut its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 267,368 shares of the company's stock after selling 29,000 shares during the period. Enliven Therapeutics comprises approximately 6.1% of Acuta Capital Partners LLC's portfolio, making the stock its 5th biggest holding. Acuta Capital Partners LLC owned about 0.55% of Enliven Therapeutics worth $6,016,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ELVN. Boxer Capital Management LLC bought a new position in Enliven Therapeutics in the 4th quarter valued at $15,106,000. Lord Abbett & CO. LLC purchased a new position in shares of Enliven Therapeutics in the 3rd quarter worth about $8,199,000. FMR LLC grew its position in Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after buying an additional 199,692 shares during the period. Pictet Asset Management Holding SA increased its holdings in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after buying an additional 135,969 shares during the last quarter. Finally, Federated Hermes Inc. bought a new stake in Enliven Therapeutics in the fourth quarter worth about $2,645,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright increased their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 21st.

Enliven Therapeutics Stock Down 7.1 %

Shares of NASDAQ:ELVN traded down $1.39 during midday trading on Wednesday, reaching $18.30. 30,684 shares of the company traded hands, compared to its average volume of 260,149. The firm's fifty day moving average price is $19.16 and its two-hundred day moving average price is $22.26. The firm has a market capitalization of $897.91 million, a price-to-earnings ratio of -9.73 and a beta of 1.07. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. Analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Activity at Enliven Therapeutics

In other news, COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the sale, the chief operating officer now owns 329,977 shares of the company's stock, valued at approximately $7,236,395.61. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the sale, the chief executive officer now owns 990,392 shares of the company's stock, valued at $20,629,865.36. This represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 76,111 shares of company stock valued at $1,516,746. Company insiders own 29.20% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.